ID
Tubo-Ovarian Abscess
search
Tubo-Ovarian Abscess
, Tuboovarian Abscess
See Also
Pelvic Inflammatory Disease
Sexually Transmitted Infection
Epidemiology
Complicates 17-20% of
Pelvic Inflammatory Disease
cases (esp. if delayed treatment)
Most common age 15 to 40 years old
Pathophysiology
See
Pelvic Inflammatory Disease
Infectious, inflammatory mass involving the ovary and fallopian tube
Infection may spread more broadly to involve other pelvic organs, as well as the bowel and
Bladder
Risk Factors
See
Pelvic Inflammatory Disease
Delayed treatment of
Pelvic Inflammatory Disease
(or incomplete treatment)
Recent genitourinary procedures (e.g. hysteroscopy, abdominal or pelvic surgery)
Diabetes Mellitus
Immunocompromised
state (e.g.
HIV Infection
)
Inflammatory Bowel Disease
Chronic
Bacterial Infection
s (e.g.
Salmonella typhi
,
Brucellosis
)
Causes
Sources
Ascending Infection (most common)
Sexually Transmitted Infection
Pelvic Inflammatory Disease
Vaginal flora
Other sources
Gastrointestinal infection spread (e.g.
Appendicitis
,
Diverticulitis
)
Inflammatory Bowel Disease
Urinary tract spread (e.g.
Pyelonephritis
)
Pelvic organ cancer
Underlying malignancy is found in up to 50% of postmenopausal patients with Tuboovarian Abscess
Causes
Infections
See
Pelvic Inflammatory Disease
Most common (
Sexually Transmitted Infection
s)
Gonorrhea
Chlamydia trachomatis
Trichomoniasis
Other organisms
Escherichia coli
(common)
Bacteroides
fragilis
Prevotella species
Anaerobic streptococcal species
Immunocompromised
state
Candida
Mycobacterium tuberculosis
Pasteurella
Streptococcus Pneumoniae
Intrauterine Device
Actinomyces israeli (covered by typical PID regimens)
Symptoms
Lower
Abdominal Pain
(90%)
Fever
(>50%)
Much more common in Tubo-Ovarian Abscess than in
Pelvic Inflammatory Disease
Chills (50%)
Nausea
(25%)
Vaginal Discharge
or
Vaginal Bleeding
(25%)
Flank Pain
(if ureteral obstruction with
Hydronephrosis
)
Signs
Ill or toxic appearance
Mucopurulent cervical discharge
Cervical motion tenderness
Significant
Adnexa
l tenderness
Palpated
Adnexal Mass
(40% of cases)
Labs
See
Pelvic Inflammatory Disease
Complete Blood Count
Leukocytosis
(77% of cases)
Imaging
Transvaginal Ultrasound
Test Sensitivity
75 to 90%
Complex
Adnexal Mass
with thick walls and increased echogenic contents
Complex free fluid in the pouch of douglas
CT Abdomen and Pelvis
with IV contrast
Preferred in non-pregnant patients with broader involvement, wider differential or toxic appearance
Test Sensitivity
90-95% with modern CT
Consider
Oral Contrast
in some cases (consult radiology)
Multiloculated, rim-enhancing, thick-walled
Adnexal Mass
, and contents with increased fluid density
Thickened fluid filled fallopian tubes with incomplete septae (50% of cases)
Contiguous inflammation (e.g. bowel wall thickening, fat stranding)
Management
See
Pelvic Inflammatory Disease
Admit all patients with Tubo-Ovarian Abscess
Early gynecology
Consultation
Antibiotic
s
Initial IV
Antibiotic
s are transitioned to 14 days of oral
Antibiotic
s
Preferred Regimens
Doxycycline
100 mg every 12 hours AND
Choose one beta lactam (
Cephalosporin
or
Penicillin
)
Ceftriaxone
1 g IV every 24 hours AND
Metronidazole
500 mg IV every 12 hours OR
Cefotetan
2 g IV every 12 hours OR
Cefoxitin
2 g every 6 hours OR
Ampicillin
-Sulbactacm (
Unasyn
) 3 g IV every 6 hours
Regimens for Severe
Penicillin Allergy
Clindamycin
900 mg IV every 8 hours AND
Gentamicin
Management varies by abscess size
Abscess 4-6 cm diameter
Resolve with
Antibiotic
s alone 85% of the time
Abscess >10 cm (or abscess rupture) typically require surgical management
Laparoscopy or percutaneous drainage required in 60% of abscess >10 cm
Management of specific associated conditions
See
Pelvic Inflammatory Disease
for concerns in HIV, pregnancy and patients with IUD
Complications
See
Pelvic Inflammatory Disease
Acute
Sepsis
(20%)
Tubo-Ovarian Abscess rupture (15%)
Chronic
Chronic Pelvic Pain
Infertility
Prognosis
Mortality 4% in
Sepsis
or abscess rupture (otherwise mortality is much lower)
References
Long and Werner in Swadron (2023) EM:Rap 23(9)
Martin and Khoujah (2023) Crit Dec Emerg Med 37(10): 22-9
Bridwell (2022) Am J Emerg Med 57:70-5 +PMID: 35525160 [PubMed]
Kairys (2023) Tubo-Ovarian Abscess, StatPearls, Treasure Island, FL [PubMed]
https://www.ncbi.nlm.nih.gov/books/NBK448125/
Type your search phrase here